PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update

PolyPid Ltd. (NASDAQ:PYPD) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 19,282 shares, a decrease of 71.7% from the December 31st total of 68,118 shares. Based on an average trading volume of 85,748 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the company’s stock are sold short. Currently, 0.2% of the company’s stock are sold short. Based on an average trading volume of 85,748 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analyst Weigh In

PYPD has been the subject of a number of research reports. Citigroup reiterated a “market outperform” rating on shares of PolyPid in a research note on Monday, December 1st. Wall Street Zen upgraded PolyPid from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of PolyPid in a research report on Monday, December 29th. Finally, Roth Mkm decreased their price objective on shares of PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $12.25.

PolyPid Stock Performance

Shares of PYPD traded down $0.13 during midday trading on Friday, hitting $4.58. 43,298 shares of the stock traded hands, compared to its average volume of 81,195. The business’s 50 day moving average price is $4.21 and its two-hundred day moving average price is $3.74. The firm has a market capitalization of $72.82 million, a PE ratio of -1.54 and a beta of 1.51. PolyPid has a 1-year low of $2.30 and a 1-year high of $5.05.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.17. As a group, equities research analysts forecast that PolyPid will post -1.79 EPS for the current fiscal year.

Institutional Investors Weigh In On PolyPid

Institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its stake in PolyPid by 56.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after buying an additional 3,500 shares during the period. Lumbard & Kellner LLC bought a new position in shares of PolyPid in the second quarter valued at approximately $135,000. Finally, AIGH Capital Management LLC boosted its holdings in shares of PolyPid by 27.0% in the second quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock valued at $4,215,000 after acquiring an additional 253,727 shares in the last quarter. Institutional investors and hedge funds own 26.47% of the company’s stock.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.